The prediction of lymph node metastasis in ductal carcinoma in situ with microinvasion by assessing lymphangiogenesis

Journal of Surgical Oncology

Volumn 102, Issue 3, 2010, Pages 225-229

  Lee, Se Kyung ^a   Cho, Eun Yoon ^a   Kim, Wan Wook ^a   Kim, Sung Hoon ^a   Hur, Sung Mo ^a   Sangmin, Kim ^a   Choe, Jun Ho ^a   Jung Han, Kim ^a   Kim, Jee Soo ^a   Lee, Jeong Eon ^a   Nam, Seok Jin ^a   Yang, Jung Hyun ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Breast neoplasms; Lymphangiogenesis; Lymphatic metastasis; Monoclonal antibody D2 40

Indexed keywords

CD34 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY D2-40; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST SURGERY; CANCER INVASION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; PREDICTION; PRIORITY JOURNAL;

ADULT; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS;

EID: 77956365687     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21607     Document Type: Article

References (38)

1. Silver SA, Tavassoli FA: Mammary ductal carcinoma in situ with microinvasion. Cancer 1998;82:2382-2390. (Pubitemid 28283445)
2. Adamovich TL, Simmons RM: Ductal carcinoma in situ with microinvasion. Am J Surg 2003;186:112-116.
3. Edge SB, Byrd DR, Compton CC, et al.: AJCC Cancer Staging Manual. New York: Springer-Verlag; 2009. pp. 347-376.
4. Wong JH, Kopald KH, Morton DL: The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg 1990;125:1298-1301; discussion 1301-1292.
5. Rosner D, Lane WW, Penetrante R: Ductal carcinoma in situ with microinvasion. A curable entity using surgery alone without need for adjuvant therapy. Cancer 1991;67:1498-1503.
6. Zavotsky J, Hansen N, Brennan MB, et al.: Lymph node metastasis from ductal carcinoma in situ with microinvasion. Cancer 1999;85:2439-2443. (Pubitemid 29244853)
7. Black MM, Speer FD, Opler SR: Structural representations of tumor-host relationships in mammary carcinoma; biologic and prognostic significance. Am J Clin Pathol 1956;26:250-265.
8. Allred DC, Harvey JM, Berardo M, et al.: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-168. (Pubitemid 28144151)
9. Chilosi M, Doglioni C, Dei Tos AP: New diagnostic markers: Podoplanin-d2-40. Pathologica 2005;97:158-159.
10. Cunnick GH, Jiang WG, Gomez KF, et al.: Lymphangiogenesis quantification using quantitative PCR and breast cancer as a model. Biochem Biophys Res Commun 2001;288:1043-1046. (Pubitemid 33140990)
11. Cunnick GH, Jiang WG, Gomez KF, et al.: Lymphangiogenesis and breast cancer metastasis. Histol Histopathol 2002;17:863-870.
12. Baluk P, McDonald DM: Markers for microscopic imaging of lymphangiogenesis and angiogenesis. Ann NY Acad Sci 2008;1131:1-12. (Pubitemid 351758499)
13. Breiteneder-Geleff S, Matsui K, Soleiman A, et al.: Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 1997;151:1141-1152. (Pubitemid 27424324)
14. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al.: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999;154:385-394. (Pubitemid 29094089)
15. Thiele W, Sleeman JP: Tumor-induced lymphangiogenesis: A target for cancer therapy? J Biotechnol 2006;124:224-241.
16. Agarwal B, Saxena R, Morimiya A, et al.: Lymphangiogenesis does not occur in breast cancer. Am J Surg Pathol 2005;29:1449-1455. (Pubitemid 41513294)
17. Schoppmann SF, Birner P, Stockl J, et al.: Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002;161:947-956. (Pubitemid 34988382)
18. Williams CS, Leek RD, Robson AM, et al.: Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol 2003;200:195-206.
19. Vleugel MM, Bos R, van der Groep P, et al.: Lack of lymphangiogenesis during breast carcinogenesis. J Clin Pathol 2004;57:746-751.
20. van der Schaft DW, Pauwels P, Hulsmans S, et al.: Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer Lett 2007;254:128-136. (Pubitemid 47058811)
21. Bono P, Wasenius VM, Heikkila P, et al.: High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Cancer Res 2004;10:7144-7149. (Pubitemid 39487698)
22. Nakamura Y, Yasuoka H, Tsujimoto M, et al.: Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat 2005;91:125-132.
23. Mohammed RA, Ellis IO, Elsheikh S, et al.: Lymphatic and angiogenic characteristics in breast cancer: Morphometric analysis and prognostic implications. Breast Cancer Res Treat 2009;113:261-273.
24. Gu Y, Qi X, Guo S: Lymphangiogenesis induced by VEGF-C and VEGF-D promotes metastasis and a poor outcome in breast carcinoma: A retrospective study of 61 cases. Clin Exp Metastasis 2008;25:717-725.
25. Van den Eynden GG, Van der Auwera I, Van Laere SJ, et al.: Induction of lymphangiogenesis in and around axillary lymph node metastases of patients with breast cancer. Br J Cancer 2006;95:1362-1366. (Pubitemid 44760086)
26. Zhang GH, Yang WT, Zhou XY, et al.: [Study of the correlation between HER-2 gene and lymphangiogenesis and their prognostic significance in human breast cancer]. Zhonghua Yi Xue Za Zhi 2007;87:155-160.
27. Zhang XH, Huang DP, Guo GL, et al.: Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer. BMC Cancer 2008;8:4.
28. Kinoshita J, Kitamura K, Kabashima A, et al.: Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat 2001;66:159-164. (Pubitemid 32521422)
29. Choi WW, Lewis MM, Lawson D, et al.: Angiogenic and lymphangiogenic microvessel density in breast carcinoma: Correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 2005;18:143-152. (Pubitemid 40128107)
30. Guo GL, Yang GL, Li ZY, et al.: The effect of cyclooxygenase-2 on lymphangiogenesis in breast cancer. Zhonghua Wai Ke Za Zhi 2008;46:132-135.
31. Cunnick GH, Jiang WG, Douglas-Jones T, et al.: Lymphangiogenesis and lymph node metastasis in breast cancer. Mol Cancer 2008;7:23. (Pubitemid 351492106)
32. Rivadeneira DE, Simmons RM, Christos PJ, et al.: Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: Analysis in more than 900 patients. J Am Coll Surg 2000;191:1-16; discussion 6-8.
33. Shoup M, Malinzak L, Weisenberger J, et al.: Predictors of axillary lymph node metastasis in T1 breast carcinoma. Am Surg 1999;65:748-752; discussion 752-743.
34. Wasserberg N, Morgenstern S, Schachter J, et al.: Risk factors for lymph node metastases in breast ductal carcinoma in situ with minimal invasive component. Arch Surg 2002;137:1249-1252. (Pubitemid 35345896)
35. Harvey JM, Clark GM, Osborne CK, et al.: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481.
36. Ismail PM, Amato P, Soyal SM, et al.: Progesterone involvement in breast development and tumorigenesis - As revealed by progesterone receptor "knockout" and "knockin" mouse models. Steroids 2003;68:779-787.
37. Ross RK, Paganini-Hill A, Wan PC, et al.: Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-332. (Pubitemid 30117736)
38. Dowsett M, Cuzick J, Wale C, et al.: Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesis-generating study. J Clin Oncol 2005;23:7512-7517. (Pubitemid 46291814)